German cardiology company Cardionovum GmbH has trumpeted results from a soon-to-be published preclinical and first-in-man clinical study of its Primus Drug-Coated Balloon (DCB). Clinical study results point to high procedural efficacy and no adverse clinical events out to six months.
Drug Eluting Balloons
In-Vivo Tests Start For New Drug-Eluting Balloon Designed to Increase Drug-in-Tissue Concentration
For a drug-eluting balloon to be effective the drug needs to elute at the right rate, which German company cardionovum believes is fast. Newly commenced in vivo studies will no doubt confirm the assertion.
Positive Results for Biotronik’s Pantera Lux Paclitaxel Releasing Balloon In Both Diabetic And Nondiabetic Subgroups
Another press release from Biotronik following last week’s EuroPCR meeting in Paris talks of six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon.
Medtronic Kicks Off Drug-Eluting Balloon SFA Study At CX34
Medtronic’s clinical ambitions are laid bare at CX34 as it announces the imminent start of its 1500 patient evaluation of peripheral artery treatment using its IN.PACT Drug-eluting balloon.
Blue Medical Trumpets New Drug-Eluting Balloon/Stent Combination
Using a Drug-coated balloon to implant a bare metal stent might just be a smart idea, at least according to Dutch Cardiovascular specialists Blue Medical in announcing the launch of their innovative new offering.
Drug Coated Balloon Effective In Drug-Eluting Stent Restenosis
A new clinical trial investigated the treatment of restenosis in a drug-eluting stent (DES) using a drug-eluting balloon. Results are significantly better than those achieved with uncoated balloon.
Bard’s Lutonix Acquisition Fuels Race For First FDA Approved Drug-Coated PTA Balloon
C. R. Bard, Inc’s acquisition of Lutonix, Inc will position it well to be the first company to gain FDA clearance for a drug coated PTA balloon in what is estimated could be a $1Bn market.
Longitudinal Compression in Drug-Eluting Stents on the Agenda
Longitudinal Compression of Drug Eluting Stents with resultant potential shrinkage will be reviewed at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco next week
Lutonix, Inc. Announces First Patient Enrollments In Three Separate Clinical Trials
Lutonix, Inc., a privately held medical device start-up, announced that patient enrollment is underway for its three simultaneous first-in-human clinical trials.
Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT™ Falcon At EuroPCR
Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain.
Unique Proprietary Drug Eluting Balloon, with Paccocath® Technology, Readied For Global Market
MEDRAD Interventional™/Possis® announced that it has reached key milestones in bringing the Paccocath® Technology closer to market.
Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT Falcon at EuroPCR
Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain.
Invatec Receives CE Mark Approval for the IN.PACT Admiral Drug Eluting Balloon
Invatec, a comprehensive innovator of interventional products, today announced the receipt of the CE Mark and the European launch of its IN.PACT™ Admiral paclitaxel-eluting PTA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain.